Intravaginal rings: Controlled release systems for contraception and prevention of transmission of sexually transmitted infections

Drug Delivery and Translational Research

Volumn 1, Issue 3, 2011, Pages 185-193

  Friend, David R ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Antibodies; Contraceptives; Dapivirine; Dual protection; Intravaginal rings; Microbicides; Tenofovir

Indexed keywords

DAPIVIRINE; ELASTOMER; ESTRADIOL; ESTRADIOL ACETATE; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETHYLENE VINYL ACETATE COPOLYMER; IMMUNOGLOBULIN G2A ANTIBODY; MICROBICIDE; POLYETHERURETHAN; RECOMBINANT PROTEIN; SILICON; TENOFOVIR;

ARTICLE; CONTROLLED DRUG RELEASE; DYSMENORRHEA; FEMALE CONTRACEPTIVE DEVICE; HERPES SIMPLEX VIRUS 2; HORMONE SUBSTITUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MENORRHAGIA; OVARY POLYCYSTIC DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SEXUALLY TRANSMITTED DISEASE; VAGINA RING; VIRUS TRANSMISSION;

EID: 84858970174     PISSN: 2190393X     EISSN: 21903948     Source Type: Journal    
DOI: 10.1007/s13346-011-0024-4     Document Type: Article

References (49)

1. Woolfson AD, Malcolm RK, Gallagher R. Drug delivery by the intravaginal route. Crit Rev Ther Drug Carrier Syst. 2000; 17(5): 509-55.
2. Mishell Jr DR, Talas M, Parlow AF, Moyer DL. Contraception by means of a silastic vaginal ring impregnated with medroxyprogesterone acetate. Am J Obstet Gynecol. 1970; 107(1): 100-7.
3. Mishell Jr DR, Lumkin ME. Contraceptive effect of varying dosages of progestogen in silastic vaginal rings. Fertil Steril. 1970; 21(2): 99-103.
4. Kerns J, Darney P. Vaginal ring contraception. Contraception. 2011; 83(2): 107-15. doi: 10. 1016/j. contraception. 2010. 07. 008.
5. Ahren T, Victor A, Lithell H, Johansson ED. Comparison of the metabolic effects of two hormonal contraceptive methods: an oral formulation and a vaginal ring. I. Carbohydrate metabolism and liver function. Contraception. 1981; 24(4): 415-27.
6. Friend DR. Pharmaceutical development of microbicide drug products. Pharm Dev Technol. 2010; 15(6): 562-81.
7. Friend DR, Doncel GF. Combining prevention of HIV-1, other sexually transmitted infections and unintended pregnancies: development of dual-protection technologies. Antivir Res. 2010; 88 Suppl 1: S47-54.
8. Malcolm K, Woolfson D, Russell J, Tallon P, McAuley L, Craig D. Influence of silicone elastomer solubility and diffusivity on the in vitro release of drugs from intravaginal rings. J Control Release. 2003; 90(2): 217-25.
9. Malcolm RK, McCullagh S, Woolfson AD, Catney M, Tallon P. A dynamic mechanical method for determining the silicone elastomer solubility of drugs and pharmaceutical excipients in silicone intravaginal drug delivery rings. Biomaterials. 2002; 23(17): 3589-94.
10. Woolfson AD, Elliott GR, Gilligan CA, Passmore CM. Design of an intravaginal ring for the controlled delivery of 17 beta-estradiol as its 3-acetate ester. J Control Release. 1999; 61(3): 319-28.
11. Geonnotti AR, Katz DF. Compartmental transport model of microbicide delivery by an intravaginal ring. J Pharm Sci. 2010; 99(8): 3514-21.
12. Cleland J, Bernstein S, Ezeh A, Faundes A, Glasier A, Innis J. Family planning: the unfinished agenda. Lancet. 2006; 368(9549): 1810-27.
13. Brache V, Faundes A. Contraceptive vaginal rings: a review. Contraception. 2010; 82(5): 418-27.
14. van Laarhoven JA, Kruft MA, Vromans H. In vitro release properties of etonogestrel and ethinyl estradiol from a contraceptive vaginal ring. Int J Pharm. 2002; 232(1-2): 163-73.
15. van den Heuvel MW, van Bragt AJ, Alnabawy AK, Kaptein MC. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception. 2005; 72(3): 168-74.
16. Timmer CJ, Mulders TM. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin Pharmacokinet. 2000; 39(3): 233-42.
17. Ahrendt HJ, Nisand I, Bastianelli C, Gomez MA, Gemzell-Danielsson K, Urdl W, et al. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone. Contraception. 2006; 74(6): 451-7.
18. Novak A, de la Loge C, Abetz L, van der Meulen EA. The combined contraceptive vaginal ring, NuvaRing: an international study of user acceptability. Contraception. 2003; 67(3): 187-94.
19. Wieder DR, Pattimakiel L. Examining the efficacy, safety, and patient acceptability of the combined contraceptive vaginal ring (NuvaRing). Int J Womens Health. 2010; 2: 401-9.
20. Massai R, Quinteros E, Reyes MV, Caviedes R, Zepeda A, Montero JC, et al. Extended use of a progesterone-releasing vaginal ring in nursing women: a phase II clinical trial. Contraception. 2005; 72(5): 352-7.
21. Massai R, Miranda P, Valdes P, Lavin P, Zepeda A, Casado ME, et al. Preregistration study on the safety and contraceptive efficacy of a progesterone-releasing vaginal ring in Chilean nursing women. Contraception. 1999; 60(1): 9-14.
22. Radomsky ML, Whaley KJ, Cone RA, Saltzman WM. Controlled vaginal delivery of antibodies in the mouse. Biol Reprod. 1992; 47(1): 133-40.
23. Sherwood JK, Zeitlin L, Whaley KJ, Cone RA, Saltzman M. Controlled release of antibodies for long-term topical passive immunoprotection of female mice against genital herpes. Nat Biotechnol. 1996; 14(4): 468-71.
24. Fuller AO, Spear PG. Anti-glycoprotein D antibodies that permit adsorption but block infection by herpes simplex virus 1 prevent virion-cell fusion at the cell surface. Proc Natl Acad Sci USA. 1987; 84(15): 5454-8.
25. Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, Ayehunie S, et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med. 2000; 6(2): 200-6.
26. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med. 2000; 6(2): 207-10.
27. Mehandru S, Wrin T, Galovich J, Stiegler G, Vcelar B, Hurley A, et al. Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2 G12, 2 F5, and 4E10. J Virol. 2004; 78(24): 14039-42.
28. Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, Hayes D, et al. Protection of macaques against pathogenic simian/human immunodeficiency virus 89. 6PD by passive transfer of neutralizing antibodies. J Virol. 1999; 73(5): 4009-18.
29. Armbruster C, Stiegler GM, Vcelar BA, Jager W, Michael NL, Vetter N, et al. A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1. AIDS. 2002; 16(2): 227-33.
30. Binley JM, Wrin T, Korber B, Zwick MB, Wang M, Chappey C, et al. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol. 2004; 78(23): 13232-52.
31. Whaley KJ, Hanes J, Shattock R, Cone RA, Friend DR. Novel approaches to vaginal delivery and safety of microbicides: biopharmaceuticals, nanoparticles, and vaccines. Antivir Res. 2010; 88 Suppl 1: S55-66.
32. Morrow RJ, Woolfson AD, Donnelly L, Curran R, Andrews G, Katinger D, et al. Sustained release of proteins from a modified vaginal ring device. Eur J Pharm Biopharm. 2011; 77(1): 3-10.
33. Woolfson AD, Malcolm RK, Toner CF, Morrow RJ, Lowry D, Jamil A, et al. Potential use of vaginal rings for prevention of heterosexual transmission of HIV: a controlled-release strategy for HIV microbicides. Am J Drug Deliv. 2006; 4(1): 7-20.
34. Malcolm RK, Woolfson AD, Toner CF, Morrow RJ, McCullagh SD. Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings. J Antimicrob Chemother. 2005; 56(5): 954-6.
35. Woolfson AD, Malcolm RK, Morrow RJ, Toner CF, McCullagh SD. Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide. Int J Pharm. 2006; 325(1-2): 82-9.
36. Malcolm RK, Edwards KL, Kiser P, Romano J, Smith TJ. Advances in microbicide vaginal rings. Antivir Res. 2010; 88 Suppl 1: S30-9.
37. van Herrewege Y, Michiels J, van Roey J, Fransen K, Kestens L, Balzarini J, et al. In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides. Antimicrob Agents Chemother. 2004; 48(1): 337-9.
38. Nel AM, Smythe SC, Habibi S, Kaptur PE, Romano JW. Pharmacokinetics of 2 dapivirine vaginal microbicide gels and their safety vs. hydroxyethyl cellulose-based universal placebo gel. J Acquir Immune Defic Syndr. 2010; 55(2): 161-9.
39. Nel AM, Coplan P, Smythe SC, McCord K, Mitchnick M, Kaptur PE, et al. Pharmacokinetic assessment of dapivirine vaginal microbicide gel in healthy, HIV-negative women. AIDS Res Hum Retroviruses. 2010; 26(11): 1181-90.
40. Nel A, Smythe S, Young K, Malcolm K, McCoy C, Rosenberg Z, et al. Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women. J Acquir Immune Defic Syndr. 2009; 51(4): 416-23.
41. Szycher M. Biostability of polyurethane elastomers: a critical review. J Biomater Appl. 1988; 3(2): 297-402.
42. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010; 329(5996): 1168-74.
43. Turpin JA. Considerations and development of topical microbicides to inhibit the sexual transmission of HIV. Expert Opin Investig Drugs. 2002; 11(8): 1077-97.
44. Herrera C, Cranage M, McGowan I, Anton P, Shattock RJ. Reverse transcriptase inhibitors as potential colorectal microbicides. Antimicrob Agents Chemother. 2009; 53(5): 1797-807.
45. Klasse PJ, Shattock R, Moore JP. Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission. Annu Rev Med. 2008; 59: 455-71.
46. Veazey RS, Klasse PJ, Schader SM, Hu Q, Ketas TJ, Lu M, et al. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature. 2005; 438(7064): 99-102.
47. Gupta KM, Pearce SM, Poursaid AE, Aliyar HA, Tresco PA, Mitchnik MA, et al. Polyurethane intravaginal ring for controlled delivery of dapivirine, a nonnucleoside reverse transcriptase inhibitor of HIV-1. J Pharm Sci. 2008; 97(10): 4228-39.
48. Johnson TJ, Gupta KM, Fabian J, Albright TH, Kiser PF. Segmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapivirine and tenofovir. Eur J Pharm Sci. 2010; 39(4): 203-12.
49. Han YA, Singh M, Saxena BB. Development of vaginal rings for sustained release of nonhormonal contraceptives and anti-HIV agents. Contraception. 2007; 76(2): 132-8. doi: 10. 1016/j. contraception. 2007. 04. 006.